D.E. Shaw & Co
KRSA

D.E. Shaw & Co’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

D.E. Shaw & Co’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-873
Closed -$136K – 5409
2022
Q1 		$136K Sell
873
-103
-11% -$2.48K ﹤0.01% 4951
2021
Q4 		$235K Sell
976
-971
-50% -$45.9K ﹤0.01% 4800
2021
Q3 		$837K Sell
1,947
-733
-27% -$48K ﹤0.01% 3748
2021
Q2 		$1.46M Buy
2,680
+2,191
+448% +$137K ﹤0.01% 3238
2021
Q1 		$191K Sell
489
-806
-62% -$60.5K ﹤0.01% 3861
2020
Q4 		$555K Buy
1,295
+598
+86% +$40.8K ﹤0.01% 3338
2020
Q3 		$593K Sell
697
-321
-32% -$36.7K ﹤0.01% 3143
2020
Q2 		$842K Buy
1,018
+396
+64% +$33.1K ﹤0.01% 3044
2020
Q1 		$231K Sell
622
-1,326
-68% -$94.6K ﹤0.01% 3586
2019
Q4 		$742K Buy
1,948
+1,163
+148% +$109K ﹤0.01% 3184
2019
Q3 		$1.33M Buy
785
+2
+0.3% +$432 ﹤0.01% 2657
2019
Q2 		$1.25M Buy
+783
New +$222K ﹤0.01% 2539

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

D.E. Shaw & Co's KRSA Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2022, closing a stake of 873 shares — an estimated $136K sold.

D.E. Shaw & Co first reported a position in KRSA in Q2 2019 and held it in 12 quarters. The position peaked at $1.46M in Q2 2021. 36 funds tracked by Wall St. Rank hold KRSA as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 873 Korsana Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $136K.
  • D.E. Shaw & Co first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • D.E. Shaw & Co's Korsana Biosciences, Inc. Common Stock position peaked at $1.46M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.